Bellicum Pharma: Up on positive interim data

Bellicum Pharmaceuticals

13/03/2018 12:07

** Drug developer's shares  BLCM.O  up ~10 pct at $8.90
premarket 
    ** Co reports interim data from trial of BPX-501, BLCM's
treatment for a type of bone marrow cancer and immune disorders
that usually occur after a stem-cell transplant
    ** BLCM says 38 pediatric patients with acute myeloid
leukemia who underwent a stem cell transplant followed by
treatment with BPX-501 showed low rates of cancer
recurrence urn:newsml:reuters.com:*:nGNX7qT7fJ
    ** Co reports high rates of disease-free survival and
overall survival in pediatric patients with primary
immunodeficiencies
    ** BLCM plans a pediatric registration trial for BPX-501 to
be initiated by 2018-end
    ** Stock down ~5 pct YTD

 (Reporting by Mrinalini Krothapalli)
 ((Mrinalini.Krothapalli@thomsonreuters.com))